共 110 条
[1]
Pusztai L(2015)Chemotherapy and the recurrence score–results as expected? Nat Rev Clin Oncol 12 690-692
[2]
Hudis CA(2015)Biology before anatomy in early breast cancer-precisely the point N Engl J Med 373 2079-2080
[3]
Partin JF(2011)Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer Ann Surg Oncol 18 3399-3406
[4]
Mamounas EP(2013)Overview of the use of Oncotype DX((R)) as an additional treatment decision tool in early breast cancer Expert Rev Anticancer Ther 13 179-194
[5]
Markopoulos C(2015)Association between use of the 21-gene recurrence score assay and receipt of chemotherapy among medicare beneficiaries with early-stage breast cancer, 2005–2009 JAMA Oncol 1 1098-1109
[6]
Dinan MA(2012)Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer J Clin Oncol 30 2218-2226
[7]
Mi X(2016)21-gene recurrence score assay as a predictor of adjuvant chemotherapy administration for early-stage breast cancer: an analysis of use, therapeutic implications, and disparity profile J Clin Oncol 375 790-791
[8]
Reed SD(2015)Racial variation in the uptake of Oncotype DX testing for early-stage breast cancer J Clin Oncol 375 717-729
[9]
Lyman GH(2016)Increasing precision in adjuvant therapy for breast cancer N Engl J Med 163 262-270
[10]
Curtis LH(2016)70-gene signature as an aid to treatment decisions in early-stage breast cancer N Engl J Med 79 516-524